Effect of Medicare Dialysis Payment Reform on Use of Erythropoiesis Stimulating Agents-Reference-Cited by-同舟云学术

Effect of Medicare Dialysis Payment Reform on Use of Erythropoiesis Stimulating Agents

Published:2014-10-30 Issue:3 Volume:50 Page:790-808
ISSN:0017-9124
Container-title:Health Services Research
language:en
Short-container-title:Health Serv Res

Author:

Swaminathan Shailender¹,Mor Vincent¹²,Mehrotra Rajnish³,Trivedi Amal N.¹²

Affiliation:

1. Department of Health Services, Policy, and Practice; School of Public Health; Brown University; Providence RI

2. Providence VA Medical Center; Providence RI

3. Kidney Research Institute; Division of Nephrology; University of Washington; Seattle WA

Publisher

Wiley

Subject

Health Policy

Reference25 articles.

1. The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin;Besarab;New England Journal of Medicine,1998

2. Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients;Brookhart;Journal of the American Medical Association,2010

3. CMS 2004 Centers for Medicare and Medicaid Services: CMS Bundled Payment for Care Initiative. September 2012 http://www.innovations.cms.gov/initiatives/bundled-payments/index.html

4. CMS 2011 Centers for Medicare and Medicaid Services: Fact Sheet. November 2011 http://www.cms.gov/apps/media/press/factsheet.asp?counter=4148

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Payment systems for dialysis and their effects: a scoping review;BMC Health Services Research;2023-01-17

2. Payment systems for dialysis and their effects: a scoping review;2022-09-01

3. Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis;Clinical Journal of the American Society of Nephrology;2022-06

4. Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width;Scientific Reports;2022-02-14

5. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial;BMC Nephrology;2021-08-21